Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Role of tipranavir in treatment of patients with multidrug-resistant HIV.

Courter JD, Teevan CJ, Li MH, Girotto JE, Salazar JC.

Ther Clin Risk Manag. 2010 Oct 5;6:431-41. doi: 10.2147/TCRM.S4207.

2.

Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.

Luna B, Townsend MU.

Clin Ther. 2007 Nov;29(11):2309-18. Review.

PMID:
18158073
3.

Tipranavir: PNU 140690, tipranivir.

[No authors listed]

Drugs R D. 2006;7(1):55-62. Review.

PMID:
16620137
4.

New developments in anti-HIV chemotherapy.

De Clercq E.

Biochim Biophys Acta. 2002 Jul 18;1587(2-3):258-75. Review.

5.
6.

New anti-HIV agents and targets.

De Clercq E.

Med Res Rev. 2002 Nov;22(6):531-65. Review.

PMID:
12369088
7.

Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.

Boyd MA, Hill AM.

Pharmacoeconomics. 2010;28 Suppl 1:17-34. doi: 10.2165/11587420-000000000-00000. Review.

PMID:
21182341
8.

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentré F, Taburet AM.

Clin Pharmacokinet. 2010;49(1):17-45. doi: 10.2165/11318110-000000000-00000. Review.

PMID:
20000887
9.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
10.

New antiretroviral drugs in clinical use.

Chearskul P, Rongkavilit C, Al-Tatari H, Asmar B.

Indian J Pediatr. 2006 Apr;73(4):335-41. Review.

PMID:
16816495
11.

Tipranavir: a novel nonpeptidic protease inhibitor of HIV.

King JR, Acosta EP.

Clin Pharmacokinet. 2006;45(7):665-82. Review.

PMID:
16802849
12.

Tipranavir: a protease inhibitor from a new class with distinct antiviral activity.

Yeni P.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S91-4. Review.

PMID:
14562864
13.

A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

Pinheiro Edos S, Antunes OA, Fortunak JM.

Antiviral Res. 2008 Sep;79(3):143-65. doi: 10.1016/j.antiviral.2008.05.001. Review.

PMID:
18571246
14.

Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Taiwo B, Murphy RL, Katlama C.

Drugs. 2010 Sep 10;70(13):1629-42. doi: 10.2165/11538020-000000000-00000. Review.

PMID:
20731472
15.

New developments in anti-HIV chemotherapy.

De Clercq E.

Curr Med Chem. 2001 Nov;8(13):1543-72. Review.

PMID:
11562282
16.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
17.

New antiretroviral drugs.

Gulick RM.

Clin Microbiol Infect. 2003 Mar;9(3):186-93. Review.

18.

Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.

Sharma PL, Nurpeisov V, Hernandez-Santiago B, Beltran T, Schinazi RF.

Curr Top Med Chem. 2004;4(9):895-919. Review.

PMID:
15134548
19.

HIV-1 antiretroviral resistance: scientific principles and clinical applications.

Tang MW, Shafer RW.

Drugs. 2012 Jun 18;72(9):e1-25. doi: 10.2165/11633630-000000000-00000. Review.

Items per page

Supplemental Content

Support Center